ProCE Banner Activity

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer


Downloadable slideset from Komal Jhaveri, MD, FACP, on the role of TROP-2‒directed antibody‒drug conjugates in the therapeutic landscape for patients with HER2-negative advanced breast cancer, including HER2-low disease.

Released: February 22, 2024



Komal Jhaveri

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.